RxDoctor Payments Data

Tibor Becske, MD

Vascular Neurology · Raleigh, NCNPI 1770598575

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (43.2%), other and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 99.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $189,697 and has fallen 99.8% since, to $312 in 2025.

$345,714in general payments, 2019–2025

Across 55 payments — averaging $6285.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$344K
  • Imperative Care, Inc$489
  • Scientia Vascular$277
  • Stryker$203
  • Route 92 Medical, Inc.$138
  • Abbott$102
  • plus $98 from 1 others
$4,500in research payments, 2019–2025

Across 1 payment — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$5K

What the payments were for

  • Royalty or licence$149,43543%
  • Consulting fees$5,8002%
  • Speaking & faculty fees$37,20011%
  • Travel & lodging$8,8463%
  • Food & beverage$9760%
  • Other$143,45841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)40$344,407
Imperative Care, Inc1$489
Scientia Vascular1$277
Stryker5$203
Route 92 Medical, Inc.2$138
Abbott1$102
AstraZeneca5$98

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$42,112
Medicare patients
57
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor14$12,457
ClopidogrelClopidogrel Bisulfate18$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$98$12,45714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other vascular neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →